Treatment of atopic dermatitis with pimecrolimus – impact on quality of life

(2268) Views  (441) Full article downloads

Authors: Hae-Hyuk Lee, Torsten Zuberbier, Margitta Worm

Published Date January 2007 Volume 2007:3(6) Pages 1021 - 1026

DOI: http://dx.doi.org/10.2147/TCRM.S

Hae-Hyuk Lee, Torsten Zuberbier, Margitta Worm

Allergy-Center-Charité (CCM), Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany

Abstract: Atopic dermatitis (AD) is a multifactorial chronic remittent skin disease which requires long-term treatment. Pimecrolimus cream 1% is a nonsteroid selective inhibitor of inflammatory cytokines and effective in the treatment of AD. Various clinical trials have shown its long-term safety and efficacy in pediatric and adult patients suffering from mild to moderate AD. In this article we discuss data which has assessed the impact of AD on the patient’s quality of life, and the consequent role of topical anti-inflammatory therapy for long-term AD treatment.

Keywords: atopic dermatitis, quality of life, pimecrolimus, ISOLATE

Readers of this article also read: